Therapeutic cancer vaccines have gained significant popularity in recent years as new
approaches for specific oncologic indications emerge. Three therapeutic cancer vaccines …

Therapeutic cancer vaccines have proven to seldom induce dramatic clinical response
when used alone, and therefore, they are being studied in combination with additional …

There are strong biologic and preclinical rationales for the development of therapeutic
cancer vaccines; however, the clinical translation of this treatment strategy has been …

With the development and regulatory approval of immune checkpoint inhibitors and adoptive
cell therapies, cancer immunotherapy has undergone a profound transformation over the …

Concurrent with US Food and Drug Administration (FDA) approval of the first therapeutic
cancer vaccine, a wide spectrum of other cancer vaccine platforms that target a diverse …

Therapeutic cancer vaccines have become increasingly qualified for use in personalized
cancer immunotherapy. A deeper understanding of tumor immunology and novel antigen …

This comprehensive review delves into the rapidly evolving arena of cancer vaccines.
Initially, we examine the intricate constitution of the tumor microenvironment (TME), a …

Clinical approval of the immune checkpoint blockade (ICB) agents for multiple cancer types
has reinvigorated the long-standing work on cancer vaccines. In the pre-ICB era, clinical …

Therapeutic vaccines represent a viable option for active immunotherapy of cancers that aim
to treat late stage disease by using a patient's own immune system. The promising results …

With the spotlight on cancer immunotherapy and the expanding use of immune checkpoint
inhibitors, strategies to improve the response rate and duration of current cancer …